Commentary & Perspectives

Why Copilots Failed in R&D and What Comes Next 

Organizations that benefit most from AI in R&D will be those that align technology with scientific reality

Share

Despite expectations that generative AI would enhance life sciences R&D productivity, its impact has been limited due to a mismatch between technology capabilities and scientific needs. Early deployments often treated AI as a mere productivity tool, neglecting the crucial requirements of traceability and reasoning necessary for scientific work. Organizations that align AI with the unique realities of research workflows—focusing on the quality and transparency of outputs—are better positioned to benefit from technology in decision-making processes by 2026.

Original Source(s)

Why Copilots Failed in R&D and What Comes Next 

  • by Yiannis Kiachopoulos

  • March 16, 2026

Related Content

RSV Vaccine Eligibility Expands

Trial data show noninferior immune response in high-risk adults aged 18 to 49 years.

Clinicians Warn of Fatal Measles Brain Disease

Doctors caution that measles infection can lead to SSPE, a rare fatal neurologic disease that may appear years later.

The New Blueprint for Vaccine Development

ReiThera’s leaders discuss platform technologies, scalable manufacturing, and the trust needed to strengthen global vaccine preparedness

  • March 12, 2026

  • 6 min